G. A. Lazar

Immunology · 2006–2017

A researcher in the Science corpus: 3 papers; trusts 1 researcher and is trusted by 1 researcher here, as inferred from the citation graph.

Subfields

Whom G. A. Lazar trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. G. Walsh

Who trusts G. A. Lazar overall

  1. P. Carter
  2. K. Imai
  3. P. Chames

Papers from G. A. Lazar's perspective

Ordered by how strongly the researchers G. A. Lazar trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
  2. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. (Journal of Clinical Oncology)
  3. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies (Journal of Experimental Medicine)
  4. The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
  5. Arming antibodies: prospects and challenges for immunoconjugates (Nature Biotechnology)
  6. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps (Nature Reviews. Cancer)
  7. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. (New England Journal of Medicine)
  8. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer (Nature)
  9. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised,… (The Lancet Oncology)
  10. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma (New England Journal of Medicine)

Their papers